Waylis Therapeutics LLC
FDA inspection history in Rahway, New Jersey, 2026
- 1
- Form 483
Every document, by year
- Form 483
2026: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2026One Form 483, at Rahway, New Jersey.
Cited most
Across all Waylis Therapeutics observations on file
- 21 CFR 314.80(b)Postmarketing reporting of adverse drug experiences1
The complete Waylis Therapeutics file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Rahway, New Jersey
One Form 483 · 2026 · 1 observation
Latest: Form 483, Feb 12, 2026 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2026-02-12 | 483 Form 483 | Rahway, New Jersey | 1 | $99 |
Investigators on these documents
FEI number 3021614574 · most recent document Feb 12, 2026
About Waylis Therapeutics LLC
How many FDA Form 483s has Waylis Therapeutics LLC received?
FDA Intel has 1 Form 483 on file for Waylis Therapeutics LLC; the most recent is dated Feb 12, 2026.
When was Waylis Therapeutics LLC last inspected by FDA?
The most recent FDA inspection document on file for Waylis Therapeutics LLC is a Form 483 dated Feb 12, 2026, for the site in Rahway, New Jersey.
What did FDA cite at Waylis Therapeutics LLC?
The regulations cited most in the observations on file for Waylis Therapeutics LLC are 21 CFR 314.80(b) (Postmarketing reporting of adverse drug experiences), 1 time.